Trials / Active Not Recruiting
Active Not RecruitingNCT04982237
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 445 (actual)
- Sponsor
- Akeso · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AK104 | IV infusion |
| DRUG | paclitaxel | IV infusion |
| DRUG | carboplatin | iv infusion |
| DRUG | cisplatin | iv infusion |
| DRUG | bevacizumab | iv infusion |
| DRUG | Placebo | iv infusion |
Timeline
- Start date
- 2021-08-27
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
- First posted
- 2021-07-29
- Last updated
- 2025-11-19
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04982237. Inclusion in this directory is not an endorsement.